# Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

> **NCT06251492** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer Metastatic
- Castration-resistant Prostate Cancer

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **DRUG:** Adebrelimab

## Key facts

- **NCT ID:** NCT06251492
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-30
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06251492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06251492, "Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06251492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*